1. Advances in the structural modification of Alzheimer's disease drug - Huperzine A.
- Author
-
Zhu X, Xu JB, Gao F, and Wan LX
- Subjects
- Humans, Structure-Activity Relationship, Molecular Structure, Acetylcholinesterase metabolism, Acetylcholinesterase chemistry, Animals, Huperzia chemistry, Alzheimer Disease drug therapy, Alkaloids chemistry, Alkaloids pharmacology, Alkaloids chemical synthesis, Sesquiterpenes chemistry, Sesquiterpenes pharmacology, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors chemical synthesis, Cholinesterase Inhibitors therapeutic use
- Abstract
Huperzine A is an alkaloid featuring a bicyclo [3.3.1] nonane scaffold with an integrated piperidine ring, which was firstly isolated from Huperzia selago in 1960. As a reversible acetylcholinesterase inhibitor, it was clinically approved in China for treatment of Alzheimer's disease in 1996. Although huperzine A shows therapeutic potential, it is often associated with adverse events, such as dizziness, nausea, and digestive disorders. To enhance the efficacy and therapeutic index of huperzine A, many structural modification efforts have been undertaken. This review comprehensively summarizes the structural modification investigations on huperzine A conducted over the past three decades, and the structure-activity relationships are also discussed. The insights from this review are expected to inspire more effective modification strategies in the future., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF